Annual report [Section 13 and 15(d), not S-K Item 405]

Related Parties

v3.26.1
Related Parties
 12 Months Ended
Dec. 31, 2025
Related Party Transactions [Abstract]  
Related Parties

Note 9 – Related Parties

 

PharmaCyte Biotech, Inc. - Series G Preferred Stock Issuance

 

On May 20, 2024, the Company entered into the Series G Purchase Agreement with the Series G Investors, including PharmaCyte Biotech, Inc. (“Pharmacyte”), pursuant to which it agreed to sell to the Series G Investors (i) an aggregate of 8,950 Series G Preferred Stock, initially convertible into up to 492,841,600 shares of the Company’s Common Stock, at a conversion price of $0.01816 per share (ii) Series G Short-Term Warrants to acquire up to an aggregate of 492,841,600 shares of Common Stock at an exercise price of $1.816 per share, and (iii) Series G Long-Term Warrants acquire up to an aggregate of 492,841,600 shares of Common Stock at an exercise price of $0.01816 per share, for aggregate gross proceeds equaling approximately $8.9 million. The interim CEO, President and Director of PharmaCyte, Joshua Silverman, serves as the Company’s Executive Chairman.

 

PharmaCyte Biotech, Inc. - Series H Preferred Stock Issuance

 

On September 2, 2025, the Company entered into the Series H Purchase Agreement with the Series H Investors, including PharmaCyte Biotech, Inc., pursuant to which it agreed to sell to the Series H Investors (i) an aggregate of 7,000 Series H Preferred Stock, initially convertible into up to 1,400,000 shares of the Company’s Common Stock, at a conversion price of $5.00 per share and (ii) Series H Warrants to acquire up to an aggregate of 1,400,000 shares of Common Stock at an exercise price of $5.00 per share, for aggregate gross proceeds equaling approximately $7 million. The interim Chief Executive Officer, President and Director of PharmaCyte, Joshua Silverman, serves as the Company’s Executive Chairman.